Eli Lilly opens Employer Connect, pricing Zepbound at $449 a month for employers

Eli Lilly launched Employer Connect on March 5, 2026, a program that sells the single-patient-use Zepbound KwikPen to employers at a flat $449 a month across all doses, with no rebates ^[1][2][3].

Through the platform, Lilly sells the KwikPen — a device that delivers four weekly injections from one pen — to network pharmacies at the discounted $449 price for every dose ^[2]. The FDA recently approved that single-patient-use version of the pen ^[2]. Dispensing runs through a dedicated network that includes HealthDyne and CenterWell ^[2]. Zepbound contains tirzepatide and is approved for adults with obesity, some overweight adults with a weight-related medical problem, and adults with moderate-to-severe obstructive sleep apnea and obesity ^[2].

The $449 figure is what Lilly charges pharmacies. Lilly says the final cost to an employer can vary based on which pharmacy and which program administrator it uses, and that employee out-of-pocket costs depend on the cost-share model the employer chooses and the dispensing and service fees it agrees to with an administrator ^[2][3]. Lilly said the arrangement does not involve rebates, which the company says gives employers clearer visibility into whether they can offer the drug ^[1].

Employers on the platform choose among more than 15 independent program administrators ^[1][2]. Those on the platform at launch are GoodRx, Mark Cuban Cost Plus Drug Company, Sesame, Teladoc Health, 9amHealth, Andel, Calibrate Health, Crux Health, eMed, FlyteHealth, Form Health, Goodpath, Ilant Health, Onsera Health, ReviveHealth, SALTA Direct Primary Care, Transcarent and Waltz Health ^[2]. Some handle core benefits functions such as enrollment, eligibility and claims, while others specialize in comprehensive obesity management with telehealth, nutrition and lifestyle support ^[1].

"Every employer is different. They all want to design things according to their unique needs and workforce," said Kevin Hern, senior vice president of Lilly Employer, in an interview ^[1]. Hern also said in Lilly's announcement: "By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care" ^[2].

List prices for Lilly's Zepbound and Mounjaro top $1,000 per month ^[1]. Lilly says roughly half of people with commercial insurance are unable to start or stay on treatment ^[1]. A Peterson-KFF Health System Tracker survey found that nearly one-fifth of firms with more than 200 workers, including 43% of those with 5,000 or more workers, covered GLP-1 drugs for weight loss as of October ^[1]. Obesity affects more than 100 million American adults and costs the U.S. economy more than $1.7 trillion a year, including $480 billion in direct medical costs and $1.24 trillion in lost productivity, according to Lilly ^[2].

Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, said: "For far too many people living with obesity, starting or staying on treatment isn't just a medical decision, it's an access decision driven by coverage and cost" ^[2].

Why it matters for patients

For employees whose health plan excludes obesity drugs, Employer Connect is a route their employer could use to add coverage. Whether any given employer does so is that employer's decision, and no participating employers were named at launch. Which companies have signed up has not been disclosed ^[1][2][3].

The $449 is a price to pharmacies, not a guaranteed price to patients. Lilly says employees pay whatever their employer does not subsidize, and that amount will differ from one plan to the next ^[1][2][3]. Because there are no rebates in the arrangement, the price employers see is the price they get, according to the company ^[1].

Employees who want to know whether Zepbound or another obesity medicine is covered under their plan, and at what cost, would need details from their own employer or plan administrator. The announcement does not describe what those cost-share models will look like in practice ^[2].

What happens next

Hern said some employers could add obesity coverage in the coming months, while others could wait until 2027 ^[1]. Lilly said it plans to expand the number of program administrators on the platform ^[1][2]. Separately, under deals Lilly and Novo Nordisk struck with President Donald Trump, Medicare will cover obesity medicines for the first time later this year ^[1].